Leading property developers have made offers for this prime property, which real estate industry sources suggest could fetch Fiat more than Rs 300 crore (Rs 3 billion).
The PhRMA's observation is significant against the backdrop of Swiss pharma major Novartis AG's decision to relocate its R&D investments from India.
The ban, although described as temporary, is being seen as a knee-jerk reaction by the state government following the attacks on Reliance Fresh and Spencer's stores and has raised several questions over its farm policy.
The patent department made this declaration on August 16 after Novartis had failed to respond to its queries within the prescribed time.
The profit margins of multinational companies importing medicines into India have been hit with the National Pharmaceutical Pricing Authority starting strict scrutiny of price approval applications for imported products.
Indian exporters of ayurvedic drugs are finding it extremely difficult to tap this high-growth segment
According to a petition filed by Quadrant in the Delhi High Court, Travel Guru allegedly copied its software solution 'Final Quadrant SuiteCase'.
Real-estate consultants and housing finance companies say the number of deals has dropped in suburbs such as Bhandup, Malad, Vasai, Kharghar and Panvel.
The Slum Rehabilitation Authority of Maharashtra has once again extended the last date for submission of expression of interest for the Rs 10,000-crore (Rs 100 billion) Dharavi Redevelopment Project to August 30.
Absence of operational manual that guides examiners, heavy backlog take a toll.
Indian pharmaceutical companies exporting medicines worth $1 billion to at least a dozen countries like Brazil, Mexico, China and Germany are finding non-tariff barriers, in the form of discriminatory treatments, hampering their export prospect.
Besides Novartis, the other companies are Roche, J&J, Glaxo and Astrazeneca.
This has prompted public health groups to call the concerns of Swiss drug major Novartis that inadequacies in Indian patent law will have negative consequences for patients and public health in India as 'bogus'.
Steve & Barry's, one of the fastest-growing retail chains in the US, is planning to set up shops in India and China.
The central government is considering an expansion of the list of fertilisers that are eligible for subsidy.
Rs 35,000 crore investment to increase capacity by 75%.
Mohit Burman, the youngest among the newly appointed corporate heads among Dabur businesses, is known to have a penchant for acquisitions.
Interestingly, the allegations against Indian arm of the world's largest pharma maker also relates to its acquisition of the Indian subsidiary of Parke Davis by Pfizer in 2000.
Individual scientists attached to research institutions and domestic companies like Lupin, Dr Reddy's and Cadila account for the rest.
Drug banks, cancer fund now health ministry's babies.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances